Navigation Links
Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
Date:12/2/2008

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Biomarkers Inc, a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the formation of a Scientific Advisory Board consisting of internationally renowned scientists and physicians at the forefront of biomarker and clinical research. The Scientific Advisory Board includes:

-- Daniel W. Chan, Ph.D., Director of the Center for Biomarker Discovery and Director, Clinical Chemistry Division, at Johns Hopkins Medical Institution. In addition to his responsibilities of heading the hospital clinical chemistry laboratory, Dr. Chan conducts cutting edge research using state of the art proteomic techniques for biomarker discovery. His overall goals are the identification and characterization of novel biomarkers for the diagnosis and treatment of cancer.

-- Johann de Bono, M.D., Ph.D., Senior Lecturer at The Institute for Cancer Research, Royal Marsden Hospital. Dr. de Bono is leader of the Prostate Cancer Team and directs the clinical drug development Phase I trials program at Royal Marsden Hospital, with a particular interest in pharmacokinetic - pharmacodynamic evaluation of targeted therapeutics.

-- John Heymach, M.D., Ph.D., Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. The goal of Dr. Heymach's clinical, translational and laboratory research is to advance the development of targeted agents, particularly angiogenesis inhibitors for non-small lung cancer, by incorporating biomarkers into clinical trials to improve patient outcomes.

-- Peter Maimonis, Ph.D. Vice President of Biological Research, Decision Biomarkers, Waltham, MA. Dr. Maimonis has been involved in the discovery and validation of tumor biomarkers for over 20 years. His research has focused on diagnostic markers for breast and colorectal cancer. He has also developed assays for many of these biomarkers, taking a number of them through FDA approval.

-- Larry Oliver, Ph.D., Scientific Director of Mayo Clinical Trial Services and Director of the Metals Laboratory in the Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, MN. Dr. Oliver's research includes performance definitions of surrogate biomarkers of efficacy, antibody-antigen binding characterization, and clinical and analytical validation of biomarkers of safety.

"We are extremely pleased to have recruited such an outstanding group of visionary thought leaders to our SAB", said Roger Dowd, President and CEO of DBI. "We look forward to their expert guidance to enable us to realize the full potential of our multiplex immunoassay technology for drug development". About Decision Biomarkers Inc Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving productivity improvement in the pharmaceutical and diagnostic industries by supplying automated, multiplex protein biomarker systems that can be used by virtually anyone, anywhere and in real time.

www.decisionbiomarkers.com


'/>"/>
SOURCE Decision Biomarkers Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
2. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
5. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
8. Scientists Using Social Media to Inform Lab Purchasing Decisions
9. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
10. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... KBioBox is pleased to announce ... extended GUIDE-Seq ananlysis. KBioBox has adapted their core technology and direct alignment algorithms ... easy to understand reports, extended indel analysis, and translocation analysis. , “The extended ...
(Date:8/21/2017)... ... August 21, 2017 , ... Boston Strategic ... experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide ... US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP ...
(Date:8/17/2017)... ... August 17, 2017 , ... CNA Finance Chief Research Analyst, ... research update on Aytu Bioscience and cited promising increases in the prescription rates ... rates for Natesto® have more than doubled since March of this year and ...
(Date:8/16/2017)... ... August 16, 2017 , ... While art and science are often thought of ... one might think. A Mesh Is Also a Snare, a group exhibition presented ... Center’s Esther Klein Gallery (EKG) on August 17 and run through September 30. An ...
Breaking Biology Technology:
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):